search
Back to results

Peripheral Immunological Effects of High-dose Vitamin D Treatment in Healthy Subjects (VDSS)

Primary Purpose

Vitamin d Deficiency

Status
Recruiting
Phase
Not Applicable
Locations
France
Study Type
Interventional
Intervention
Vitamin D
Placebo
Sponsored by
Centre Hospitalier Universitaire de Nīmes
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional other trial for Vitamin d Deficiency focused on measuring Multiple sclerosis, Immunomodulation, lymphocyte subset

Eligibility Criteria

18 Years - 65 Years (Adult, Older Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria: The patient must have given their free and informed consent and signed the consent form The patient must be a member or beneficiary of a health insurance plan Women of childbearing potential must have effective contraception during the study period. Effective contraception is defined by a low failure rate (less than 1% per year) when used correctly and consistently, such as implants, injectables, oral contraceptives, IUDs, abstinence, or partner vasectomy. A urine pregnancy test will be performed at inclusion. Exclusion Criteria: The subject is participating in another therapeutic study, or is in a period of exclusion determined by a previous study The subject is unable to express their consent It is impossible to give the subject informed information The patient is under safeguard of justice or state guardianship Pregnant or breastfeeding Infectious disease or vaccination within previous 3 months Chronic psychiatric disease, or disease that, in the opinion of the investigator ,may put the patient at risk or affect compliance. Chronic inflammatory or dysimmune disease or subject on immunomodulatory or immunosuppressive therapy (including corticosteroids) within the last 3 months. Uncontrolled epilepsy. Known vitamin D deficiency secondary to active or other digestive disease (celiac disease, IBD, gastrectomy or bypass, cirrhosis, short bowel syndrome, nephrotic syndrome, hyperthyroidism, hypoparathyroidism, cancer, granulomatous pathology, lymphoma, rickettsiosis). History of hypercalcemia, osteopenia or osteoporosis, urinary lithiasis, heart rhythm disorders. Pathology requiring a daily intake of more than 1 gram of Calcium. Contraindication to vitamin D3 treatment as mentioned on the VIDAL documentation of UVEDOSE. Treatment affecting vitamin D metabolism other than corticosteroids: anti-epileptic drugs [phenobarbital, primidone, phenytoin], rifampicin, isoniazid, ketoconazole, 5-FU and leucovorin, thiazide diuretic. Active vitamin supplementation or dietary supplements rich in vitamin D. Present or past neurological symptoms that may suggest an undiagnosed inflammatory neurological pathology.

Sites / Locations

  • CHU de NîmesRecruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Placebo Comparator

Arm Label

Vitamin D

Control

Arm Description

Outcomes

Primary Outcome Measures

Change in Lymphocyte T CD4+ cells since baseline
Percentage variation measured by Fluorescence Activated Cell Sorting of cells CD3+/CD4+
Change in T helper1 (Th1) Lymphocyte T CD4+ cells since baseline
Percentage variation measured by Fluorescence Activated Cell Sorting of cells CXCR3+ /CCR6-
Change in Th1*Lymphocyte T CD4+ cells since baseline
Percentage variation measured by Fluorescence Activated Cell Sorting of cells CXCR3+/CCR+
Change in naive Lymphocyte T CD4+ cells since baseline
Percentage variation measured by Fluorescence Activated Cell Sorting of cells CD45RA+/CCR7+
Change in effector memory Lymphocyte T CD4+ cells since baseline
Percentage variation measured by Fluorescence Activated Cell Sorting of cells CD45RA-/CCR7-
Change in central memory Lymphocyte T CD4+ cells since baseline
Percentage variation measured by Fluorescence Activated Cell Sorting of cells CD45RA-/CCR7+
Change in Teffector memory RA+ Lymphocyte T CD4+ cells since baseline
Percentage variation measured by Fluorescence Activated Cell Sorting of cells CD45RA+/CCR7-
Change in FOXP3 Treg / Treg Lymphocyte T CD4+ cells since baseline
Percentage variation measured by Fluorescence Activated Cell Sorting of cells CD25+/CD127+/FOXP3+
Change in naive Treg Lymphocyte T CD4+ cells since baseline
Percentage variation measured by Fluorescence Activated Cell Sorting of cells CD45RA+/FOXP3+
Change in memory Treg Lymphocyte T CD4+ cells since baseline
Percentage variation measured by Fluorescence Activated Cell Sorting of cells CD45RA-/FOXP3+
Change in Tr1 Lymphocyte T cells CD4+ since baseline
Percentage variation measured by Fluorescence Activated Cell Sorting of cells CD49b+/LAG3+
Change in Lymphocyte T CD8+ cells since baseline
Percentage variation measured by Fluorescence Activated Cell Sorting of cells CD3+/CD4-
Change in naive Lymphocyte T CD8+ cells since baseline
Percentage variation measured by Fluorescence Activated Cell Sorting of cells CD45RA+/CCR7+
Change in effector memory Lymphocyte T CD8+ cells since baseline
Percentage variation measured by Fluorescence Activated Cell Sorting of cells CD45RA-/CCR7-
Change in central memory Lymphocyte T CD8+ cells since baseline
Percentage variation measured by Fluorescence Activated Cell Sorting of cells CD45RA-/CCR7+
Change in Teffector memory RA+ Lymphocyte T CD8+ cells since baseline
Percentage variation measured by Fluorescence Activated Cell Sorting of cells CD45RA+/CCR7-
Change in Tc1 Lymphocyte T CD8+ cells since baseline
Percentage variation measured by Fluorescence Activated Cell Sorting of cells CXCR3+/CCR6-
Change in Tc1* Lymphocyte T CD8+ cells since baseline
Percentage variation measured by Fluorescence Activated Cell Sorting of cells CXCR3+/CCR6+
Change in Tc2 Lymphocyte T CD8+ cells since baseline
Percentage variation measured by Fluorescence Activated Cell Sorting of cells CXCR3-/CCR6-
Change in Tc17 Lymphocyte T CD8+ cells since baseline
Percentage variation measured by Fluorescence Activated Cell Sorting of cells CXCR3-/CCR6+
Change in CD8 Tcreg / TcReg Lymphocyte T CD8+ cells since baseline
Percentage variation measured by Fluorescence Activated Cell Sorting of cells CD25+/CD127+/FOXP3+
Change in naive Tcreg Lymphocyte T CD8+ cells since baseline
Percentage variation measured by Fluorescence Activated Cell Sorting of cells CD45RA+/FOXP3+
Change in memory Tcreg Lymphocyte T CD8+ cells since baseline
Percentage variation measured by Fluorescence Activated Cell Sorting of cells CD45RA-/FOXP3+
Change in Lymphocyte B cells since baseline
Percentage variation measured by Fluorescence Activated Cell Sorting of cells CD19+

Secondary Outcome Measures

lymphocyte subpopulations change in CD6 phenotype after 3 months of high dose vitamin D treatment or placebo
Measured by Fluorescence Activated Cell Sorting of cells
lymphocyte subpopulations change in CD162 phenotype after 3 months of high dose vitamin D treatment or placebo
Measured by Fluorescence Activated Cell Sorting of cells
lymphocyte subpopulations change in CD226 phenotype after 3 months of high dose vitamin D treatment or placebo
Measured by Fluorescence Activated Cell Sorting of cells
lymphocyte subpopulations change in CD46 phenotype after 3 months of high dose vitamin D treatment or placebo
Measured by Fluorescence Activated Cell Sorting of cells
lymphocyte subpopulations change in CD11a phenotype after 3 months of high dose vitamin D treatment or placebo
Measured by Fluorescence Activated Cell Sorting of cells
lymphocyte subpopulations change in CD49d phenotype after 3 months of high dose vitamin D treatment or placebo
Measured by Fluorescence Activated Cell Sorting of cells
lymphocyte subpopulations change in CLA phenotype after 3 months of high dose vitamin D treatment or placebo
Measured by Fluorescence Activated Cell Sorting of cells
Change in production of cytokine IL-10 in lymphocyte subpopulations after 3 months of high dose vitamin D treatment or placebo
Measured by Fluorescence Activated Cell Sorting of cells
Change in production of cytokine IFNg in lymphocyte subpopulations after 3 months of high dose vitamin D treatment or placebo
Measured by Fluorescence Activated Cell Sorting of cells
Change in production of cytokine IL-17 in lymphocyte subpopulations after 3 months of high dose vitamin D treatment or placebo
Measured by Fluorescence Activated Cell Sorting of cells
Change in plasma Vitamin D levels 3 months after baseline of high dose Vitamin D treatment versus placebo
Determination of 25-OH-D2 and 25-OH-D3 forms in nmol/L in plasma with the "vitamin D total II" kit
Change in 16sRNA levels 3 months after baseline of high dose Vitamin D treatment versus placebo
Nature of gut microbiota taxonomy 3 months after high dose Vitamin D treatment versus placebo
Number of operational taxonomic units
Nature of blood microbiota taxonomy 3 months after high dose Vitamin D treatment versus placebo
Number of operational taxonomic units
Percentage of gut microbiota taxonomy 3 months after high dose Vitamin D treatment versus placebo
Percentage of operational taxonomic units
Percentage of blood microbiota taxonomy 3 months after high dose Vitamin D treatment versus placebo
Percentage of operational taxonomic units
Diversity of gut microbiota 3 months after high dose Vitamin D treatment versus placebo
Shannon index
Diversity of blood microbiota 3 months after high dose Vitamin D treatment versus placebo
Shannon index
Beta diversity of gut microbiota 3 months after high dose Vitamin D treatment versus placebo
Bray-Curtis index
Beta diversity of blood microbiota 3 months after high dose Vitamin D treatment versus placebo
Bray-Curtis index
Describing the genetic determinants of vitamin D response using a Single Nucleotide Polymorphism (SNP) database
Description of individual SNPs

Full Information

First Posted
December 8, 2022
Last Updated
May 4, 2023
Sponsor
Centre Hospitalier Universitaire de Nīmes
search

1. Study Identification

Unique Protocol Identification Number
NCT05654818
Brief Title
Peripheral Immunological Effects of High-dose Vitamin D Treatment in Healthy Subjects
Acronym
VDSS
Official Title
Peripheral Immunological Effects of High-dose Vitamin D Treatment in Healthy Subjects: Randomized, Single-center, Double-blind Trial
Study Type
Interventional

2. Study Status

Record Verification Date
May 2023
Overall Recruitment Status
Recruiting
Study Start Date
April 13, 2023 (Actual)
Primary Completion Date
July 2024 (Anticipated)
Study Completion Date
July 2024 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Centre Hospitalier Universitaire de Nīmes

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No

5. Study Description

Brief Summary
Vitamin D deficiency is associated with the risk of developing MS. Vitamin D treatment has therefore been tested as a background treatment for this pathology, with a seemingly modest clinical effect. Indeed, the first therapeutic trials using high doses of vitamin D (SOLAR and CHOLINE) did not show a significant effect on short-term relapses. However, these two studies showed a significant decrease in the radiological activity of MS on MRI, suggesting a significant immunomodulatory efficacy but a weak clinical benefit in the short term. Vitamin D has a pleiotropic effect on the immune system inducing overall immunomodulation through transcriptomic modulations, under the control of many individual genetic factors. However, in vivo, only one therapeutic trial has compared the immunological effect of Vitamin D in healthy subjects and in patients with a first demyelinating episode. Analysis of PBMC by flow cytometric cell sorting based on a very small number of markers (CD3, CD8, IL-17, IFN-g) did not find any significant quantitative modulation of Th17 or of their production of IL-10, IL-17 and IFN-g after treatment with Vitamin D measured by ELISA. However, the evolution of anti-inflammatory lymphocyte populations has not been evaluated. A few in vitro studies suggest that the effect of vitamin D may be incomplete on the lymphocytes of MS patients. The study investigators will use an immunological FACS approach to describe activation markers and measure the intensity of changes induced in healthy subjects after 3 months of high-dose cholecalciferol versus placebo treatment using the same protocol as the D-Lay MS (NCT01817166) study.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Vitamin d Deficiency
Keywords
Multiple sclerosis, Immunomodulation, lymphocyte subset

7. Study Design

Primary Purpose
Other
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
ParticipantInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
56 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Vitamin D
Arm Type
Experimental
Arm Title
Control
Arm Type
Placebo Comparator
Intervention Type
Drug
Intervention Name(s)
Vitamin D
Intervention Description
100,000 UI
Intervention Type
Drug
Intervention Name(s)
Placebo
Intervention Description
The placebo is identical in appearance to the active treatment: a drinkable solution in ampoules that is clear, yellowish in color with a slightly lemony odor and an oily, slightly sweet, lemony taste.
Primary Outcome Measure Information:
Title
Change in Lymphocyte T CD4+ cells since baseline
Description
Percentage variation measured by Fluorescence Activated Cell Sorting of cells CD3+/CD4+
Time Frame
Month 3
Title
Change in T helper1 (Th1) Lymphocyte T CD4+ cells since baseline
Description
Percentage variation measured by Fluorescence Activated Cell Sorting of cells CXCR3+ /CCR6-
Time Frame
Month 3
Title
Change in Th1*Lymphocyte T CD4+ cells since baseline
Description
Percentage variation measured by Fluorescence Activated Cell Sorting of cells CXCR3+/CCR+
Time Frame
Month 3
Title
Change in naive Lymphocyte T CD4+ cells since baseline
Description
Percentage variation measured by Fluorescence Activated Cell Sorting of cells CD45RA+/CCR7+
Time Frame
Month 3
Title
Change in effector memory Lymphocyte T CD4+ cells since baseline
Description
Percentage variation measured by Fluorescence Activated Cell Sorting of cells CD45RA-/CCR7-
Time Frame
Month 3
Title
Change in central memory Lymphocyte T CD4+ cells since baseline
Description
Percentage variation measured by Fluorescence Activated Cell Sorting of cells CD45RA-/CCR7+
Time Frame
Month 3
Title
Change in Teffector memory RA+ Lymphocyte T CD4+ cells since baseline
Description
Percentage variation measured by Fluorescence Activated Cell Sorting of cells CD45RA+/CCR7-
Time Frame
Month 3
Title
Change in FOXP3 Treg / Treg Lymphocyte T CD4+ cells since baseline
Description
Percentage variation measured by Fluorescence Activated Cell Sorting of cells CD25+/CD127+/FOXP3+
Time Frame
Month 3
Title
Change in naive Treg Lymphocyte T CD4+ cells since baseline
Description
Percentage variation measured by Fluorescence Activated Cell Sorting of cells CD45RA+/FOXP3+
Time Frame
Month 3
Title
Change in memory Treg Lymphocyte T CD4+ cells since baseline
Description
Percentage variation measured by Fluorescence Activated Cell Sorting of cells CD45RA-/FOXP3+
Time Frame
Month 3
Title
Change in Tr1 Lymphocyte T cells CD4+ since baseline
Description
Percentage variation measured by Fluorescence Activated Cell Sorting of cells CD49b+/LAG3+
Time Frame
Month 3
Title
Change in Lymphocyte T CD8+ cells since baseline
Description
Percentage variation measured by Fluorescence Activated Cell Sorting of cells CD3+/CD4-
Time Frame
Month 3
Title
Change in naive Lymphocyte T CD8+ cells since baseline
Description
Percentage variation measured by Fluorescence Activated Cell Sorting of cells CD45RA+/CCR7+
Time Frame
Month 3
Title
Change in effector memory Lymphocyte T CD8+ cells since baseline
Description
Percentage variation measured by Fluorescence Activated Cell Sorting of cells CD45RA-/CCR7-
Time Frame
Month 3
Title
Change in central memory Lymphocyte T CD8+ cells since baseline
Description
Percentage variation measured by Fluorescence Activated Cell Sorting of cells CD45RA-/CCR7+
Time Frame
Month 3
Title
Change in Teffector memory RA+ Lymphocyte T CD8+ cells since baseline
Description
Percentage variation measured by Fluorescence Activated Cell Sorting of cells CD45RA+/CCR7-
Time Frame
Month 3
Title
Change in Tc1 Lymphocyte T CD8+ cells since baseline
Description
Percentage variation measured by Fluorescence Activated Cell Sorting of cells CXCR3+/CCR6-
Time Frame
Month 3
Title
Change in Tc1* Lymphocyte T CD8+ cells since baseline
Description
Percentage variation measured by Fluorescence Activated Cell Sorting of cells CXCR3+/CCR6+
Time Frame
Month 3
Title
Change in Tc2 Lymphocyte T CD8+ cells since baseline
Description
Percentage variation measured by Fluorescence Activated Cell Sorting of cells CXCR3-/CCR6-
Time Frame
Month 3
Title
Change in Tc17 Lymphocyte T CD8+ cells since baseline
Description
Percentage variation measured by Fluorescence Activated Cell Sorting of cells CXCR3-/CCR6+
Time Frame
Month 3
Title
Change in CD8 Tcreg / TcReg Lymphocyte T CD8+ cells since baseline
Description
Percentage variation measured by Fluorescence Activated Cell Sorting of cells CD25+/CD127+/FOXP3+
Time Frame
Month 3
Title
Change in naive Tcreg Lymphocyte T CD8+ cells since baseline
Description
Percentage variation measured by Fluorescence Activated Cell Sorting of cells CD45RA+/FOXP3+
Time Frame
Month 3
Title
Change in memory Tcreg Lymphocyte T CD8+ cells since baseline
Description
Percentage variation measured by Fluorescence Activated Cell Sorting of cells CD45RA-/FOXP3+
Time Frame
Month 3
Title
Change in Lymphocyte B cells since baseline
Description
Percentage variation measured by Fluorescence Activated Cell Sorting of cells CD19+
Time Frame
Month 3
Secondary Outcome Measure Information:
Title
lymphocyte subpopulations change in CD6 phenotype after 3 months of high dose vitamin D treatment or placebo
Description
Measured by Fluorescence Activated Cell Sorting of cells
Time Frame
Month 3
Title
lymphocyte subpopulations change in CD162 phenotype after 3 months of high dose vitamin D treatment or placebo
Description
Measured by Fluorescence Activated Cell Sorting of cells
Time Frame
Month 3
Title
lymphocyte subpopulations change in CD226 phenotype after 3 months of high dose vitamin D treatment or placebo
Description
Measured by Fluorescence Activated Cell Sorting of cells
Time Frame
Month 3
Title
lymphocyte subpopulations change in CD46 phenotype after 3 months of high dose vitamin D treatment or placebo
Description
Measured by Fluorescence Activated Cell Sorting of cells
Time Frame
Month 3
Title
lymphocyte subpopulations change in CD11a phenotype after 3 months of high dose vitamin D treatment or placebo
Description
Measured by Fluorescence Activated Cell Sorting of cells
Time Frame
Month 3
Title
lymphocyte subpopulations change in CD49d phenotype after 3 months of high dose vitamin D treatment or placebo
Description
Measured by Fluorescence Activated Cell Sorting of cells
Time Frame
Month 3
Title
lymphocyte subpopulations change in CLA phenotype after 3 months of high dose vitamin D treatment or placebo
Description
Measured by Fluorescence Activated Cell Sorting of cells
Time Frame
Month 3
Title
Change in production of cytokine IL-10 in lymphocyte subpopulations after 3 months of high dose vitamin D treatment or placebo
Description
Measured by Fluorescence Activated Cell Sorting of cells
Time Frame
Month 3
Title
Change in production of cytokine IFNg in lymphocyte subpopulations after 3 months of high dose vitamin D treatment or placebo
Description
Measured by Fluorescence Activated Cell Sorting of cells
Time Frame
Month 3
Title
Change in production of cytokine IL-17 in lymphocyte subpopulations after 3 months of high dose vitamin D treatment or placebo
Description
Measured by Fluorescence Activated Cell Sorting of cells
Time Frame
Month 3
Title
Change in plasma Vitamin D levels 3 months after baseline of high dose Vitamin D treatment versus placebo
Description
Determination of 25-OH-D2 and 25-OH-D3 forms in nmol/L in plasma with the "vitamin D total II" kit
Time Frame
Month 3
Title
Change in 16sRNA levels 3 months after baseline of high dose Vitamin D treatment versus placebo
Time Frame
Month 3
Title
Nature of gut microbiota taxonomy 3 months after high dose Vitamin D treatment versus placebo
Description
Number of operational taxonomic units
Time Frame
Month 3
Title
Nature of blood microbiota taxonomy 3 months after high dose Vitamin D treatment versus placebo
Description
Number of operational taxonomic units
Time Frame
Month 3
Title
Percentage of gut microbiota taxonomy 3 months after high dose Vitamin D treatment versus placebo
Description
Percentage of operational taxonomic units
Time Frame
Month 3
Title
Percentage of blood microbiota taxonomy 3 months after high dose Vitamin D treatment versus placebo
Description
Percentage of operational taxonomic units
Time Frame
Month 3
Title
Diversity of gut microbiota 3 months after high dose Vitamin D treatment versus placebo
Description
Shannon index
Time Frame
Month 3
Title
Diversity of blood microbiota 3 months after high dose Vitamin D treatment versus placebo
Description
Shannon index
Time Frame
Month 3
Title
Beta diversity of gut microbiota 3 months after high dose Vitamin D treatment versus placebo
Description
Bray-Curtis index
Time Frame
Month 3
Title
Beta diversity of blood microbiota 3 months after high dose Vitamin D treatment versus placebo
Description
Bray-Curtis index
Time Frame
Month 3
Title
Describing the genetic determinants of vitamin D response using a Single Nucleotide Polymorphism (SNP) database
Description
Description of individual SNPs
Time Frame
Month 3

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
65 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: The patient must have given their free and informed consent and signed the consent form The patient must be a member or beneficiary of a health insurance plan Women of childbearing potential must have effective contraception during the study period. Effective contraception is defined by a low failure rate (less than 1% per year) when used correctly and consistently, such as implants, injectables, oral contraceptives, IUDs, abstinence, or partner vasectomy. A urine pregnancy test will be performed at inclusion. Exclusion Criteria: The subject is participating in another therapeutic study, or is in a period of exclusion determined by a previous study The subject is unable to express their consent It is impossible to give the subject informed information The patient is under safeguard of justice or state guardianship Pregnant or breastfeeding Infectious disease or vaccination within previous 3 months Chronic psychiatric disease, or disease that, in the opinion of the investigator ,may put the patient at risk or affect compliance. Chronic inflammatory or dysimmune disease or subject on immunomodulatory or immunosuppressive therapy (including corticosteroids) within the last 3 months. Uncontrolled epilepsy. Known vitamin D deficiency secondary to active or other digestive disease (celiac disease, IBD, gastrectomy or bypass, cirrhosis, short bowel syndrome, nephrotic syndrome, hyperthyroidism, hypoparathyroidism, cancer, granulomatous pathology, lymphoma, rickettsiosis). History of hypercalcemia, osteopenia or osteoporosis, urinary lithiasis, heart rhythm disorders. Pathology requiring a daily intake of more than 1 gram of Calcium. Contraindication to vitamin D3 treatment as mentioned on the VIDAL documentation of UVEDOSE. Treatment affecting vitamin D metabolism other than corticosteroids: anti-epileptic drugs [phenobarbital, primidone, phenytoin], rifampicin, isoniazid, ketoconazole, 5-FU and leucovorin, thiazide diuretic. Active vitamin supplementation or dietary supplements rich in vitamin D. Present or past neurological symptoms that may suggest an undiagnosed inflammatory neurological pathology.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Eric Thouvenot
Phone
04.66.68.32.51
Email
eric.thouvenot@chu-nimes.fr
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Eric Thouvenot
Organizational Affiliation
CHU de Nimes
Official's Role
Principal Investigator
Facility Information:
Facility Name
CHU de Nîmes
City
Nîmes
Country
France
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Anissa Megzari
Phone
04.66.68.42.36
Email
drc@chu-nimes.fr
First Name & Middle Initial & Last Name & Degree
Eric Thouvenot
First Name & Middle Initial & Last Name & Degree
Manon Rival
First Name & Middle Initial & Last Name & Degree
Perinne Schmitt

12. IPD Sharing Statement

Learn more about this trial

Peripheral Immunological Effects of High-dose Vitamin D Treatment in Healthy Subjects

We'll reach out to this number within 24 hrs